Association Between Glycosylated Hemoglobin and Intentional Weight Loss in Overweight and Obese Patients With Type 2 Diabetes Mellitus: A Retrospective Cohort Study

The Diabetes Educator

Volumn 38, Issue 3, 2012, Pages 417-426

  Shantha, Ghanshyam Palamaner Subash ^a   Kumar, Anita Ashok ^a   Kahan, Scott ^a,b   Cheskin, Lawrence J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; BLOOD; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RETROSPECTIVE STUDY; RISK REDUCTION; WEIGHT REDUCTION;

BLOOD GLUCOSE; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; RETROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; WEIGHT LOSS; WEIGHT REDUCTION PROGRAMS;

EID: 84861137983     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721712443293     Document Type: Article

References (35)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-241.
2. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096.
3. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff (Millwood). 2003;suppl Web exclusives:W3-219–W3-226.
4. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76-79.
5. Pi-Sunyer X, Blackburn G, Brancati FL et al. Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374-1383.
6. Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
7. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141(6):413-420.
8. Krzentowski G, Zhang L, Albert A, Lefèbvre P. Another look at the implications of the DCCT study. Ann Endocrinol (Paris). 2004;65(5):429-435.
9. Miller SA, Mancuso CA, Boutin-Foster C et al. Associations between posttraumatic stress disorder and hemoglobin A1C in low-income minority patients with diabetes. Gen Hosp Psychiatry. 2011;33(2):116-122.
10. Christman AL, Selvin E, Margolis DJ, Lazarus GS, Garza LA. Hemoglobin A1c predicts healing rate in diabetic wounds. J Invest Dermatol. 2011;131(10):2121-2127.
11. Ren X, Zhang X, Zhang X et al. Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. Public Health. 2009;123(8):540-544.
12. Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB, Cryer B. Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig Dis Sci. 2008;53(9):2486-2494.
13. Siddiqui AA, Maddur H, Naik S, Cryer B. The association of elevated HbA1c on the behavior of adenomatous polyps in patients with type-II diabetes mellitus. Dig Dis Sci. 2008;53(4):1042-1047.
14. Joshu CE, Prizment AE, Dluzniewski PJ et al. Glycated hemoglobin and cancer incidence and mortality in the atherosclerosis in communities (ARIC) study, 1990-2006 [published online ahead of print December 13, 2011]. Int J Cancer. doi:10.1002/ijc.27394.
15. Selvin E, Ning Y, Steffes MW et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes. 2011;60(1):298-305.
16. Huxley RR, Alonso A, Lopez FL et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart. 2012;98(2):133-138.
17. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
18. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
19. Redmon JB, Bertoni AG, Connelly S et al. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care. 2010;33(6):1153-1158.
20. Appel LJ, Clark JM, Yeh HC et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med. 2011;365(21):1959-1968.
21. Jeffrey SF, Eleftheria MF. Obesity. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. Vol. 1. 16th ed. New York, NY: McGraw Hill; 2005:422-423.
22. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
23. Hosmer D, Lemeshow S. Applied Logistic Regression Analysis. 2nd ed. New York, NY: John Wiley & Sons; 2000.
24. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP; 2009.
25. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541-549.
26. Groop L. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-747.
27. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia on type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963-1972.
28. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(2):CD003639.
29. Sjostrom L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693.
30. Dixon JB, O'Brien PE, Playfair J et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-323.
31. Dixon JB. Obesity and diabetes: the impact of bariatric surgery on type-2 diabetes. World J Surg. 2009;33(10):2014-2021.
32. Sumithran P, Prendergast LA, Delbridge E et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604.
33. Edwards C, Hindle AK, Fu S, Brody F. Downregulation of leptin and resistin expression in blood following bariatric surgery. Surg Endosc. 2011;25(6):1962-1968.
34. Yao PM, Tabas I. Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway. J Biol Chem. 2001;276(45):42468-42476.
35. Cardellach F, Alonso JR, López S, Casademont J, Miró O. Effect of smoking cessation on mitochondrial respiratory chain function. J Toxicol Clin Toxicol. 2003;41(3):223-228.